Affordable Access

Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism

Authors
  • Kim, Young-Seon
  • Lee, Yoon-Mi
  • Oh, Taek-In
  • Shin, Dong Hoon
  • Kim, Geon-Hee
  • Kan, Sang-Yeon
  • Kang, Hyeji
  • Kim, Ji Hyung
  • Kim, Byeong Mo
  • Yim, Woo Jong
  • Lim, Ji-Hong
Publication Date
Oct 12, 2018
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

however, the sensitizing effect of emodin on sorafenib-based HCC therapy has not been evaluated. Here, we demonstrate that emodin significantly improved the anti-cancer effect of sorafenib in HCC cells, such as HepG2, Hep3B, Huh7, SK-HEP-1, and PLC/PRF5. Mechanistically, emodin inhibits sterol regulatory element-binding protein-2 (SREBP-2) transcriptional activity, which suppresses cholesterol biosynthesis and oncogenic protein kinase B (AKT) signaling. Additionally, attenuated cholesterol synthesis and oncogenic AKT signaling inactivated signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor. Furthermore, emodin synergistically increased cell cycle arrest in the G1 phase and apoptotic cells in the presence of sorafenib. Animal models xenografted with HepG2 or SK-HEP-1 cells also showed that the combination of emodin and sorafenib was sufficient to inhibit tumor growth. Overall, these results suggested that the combination of emodin and sorafenib may offer a potential therapy for patients with advanced HCC.

Report this publication

Statistics

Seen <100 times